MetaVia Inc. (NASDAQ:MTVA) Short Interest Update

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 64,283 shares, an increase of 13.3% from the March 31st total of 56,743 shares. Based on an average daily trading volume, of 143,593 shares, the short-interest ratio is currently 0.4 days. Approximately 1.3% of the shares of the company are sold short.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Stock Performance

Shares of NASDAQ MTVA opened at $1.44 on Friday. The firm has a market capitalization of $7.44 million, a P/E ratio of -0.17 and a beta of 0.35. MetaVia has a one year low of $1.17 and a one year high of $19.03. The company’s fifty day moving average is $1.45 and its two-hundred day moving average is $5.22.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. HC Wainwright lowered their price objective on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research report on Friday, April 24th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, MetaVia has an average rating of “Hold” and a consensus price target of $26.50.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.